December 30, 2025
FOCUS on Drug Failures. On December 22nd AstraZeneca reported on the LATIFY Phase III trial of ATR inhibitor ceralasertib (AZD6738) in combination with Imfinzi (Durvalumab), which […]
June 26, 2025
FOCUS on Drug Approvals. On June 23rd, the FDA approved datopotamab deruxtecan-dlnk (AstraZeneca and Daiichi Sankyo’s Datroway) for non-small cell lung cancer. The antibody-drug conjugate (or […]
July 9, 2024
Natural Product-Inspired Drugs. Camptothecin, an alkaloid isolated from Camptotheca acuminata, is a potent inhibitor of DNA topoisomerase I. Numerous useful analogs of camptothecin have been synthesized: […]